LQDA Valuation

Liquidia Corp

Add to Watchlist

Advanced Chart

27.680

+0.22(0.801%)1D

Overview
Forecast
Valuation
Earnings

LQDA Relative Valuation

LQDA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LQDA is overvalued; if below, it's undervalued.

Historical Valuation

Liquidia Corp (LQDA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 10.25 is considered Undervalued compared with the five-year average of -9.79. The fair price of Liquidia Corp (LQDA) is between 35.83 to 101.28 according to relative valuation methord. Compared to the current price of 27.68 USD , Liquidia Corp is Undervalued By 22.75%.

Relative Value

Fair Zone

35.83-101.28

Current Price：27.68

22.75%

Undervalued

-119.21

Trailing

Forward

-44.01

EV/EBITDA

Liquidia Corp. (LQDA) has a current EV/EBITDA of -44.01. The 5-year average EV/EBITDA is -6.60. The thresholds are as follows: Strongly Undervalued below -19.32, Undervalued between -19.32 and -12.96, Fairly Valued between -0.23 and -12.96, Overvalued between -0.23 and 6.13, and Strongly Overvalued above 6.13. The current Forward EV/EBITDA of -44.01 falls within the Strongly Undervalued range.

-967.60

EV/EBIT

Liquidia Corp. (LQDA) has a current EV/EBIT of -967.60. The 5-year average EV/EBIT is -27.18. The thresholds are as follows: Strongly Undervalued below -278.89, Undervalued between -278.89 and -153.03, Fairly Valued between 98.68 and -153.03, Overvalued between 98.68 and 224.54, and Strongly Overvalued above 224.54. The current Forward EV/EBIT of -967.60 falls within the Strongly Undervalued range.

10.25

Liquidia Corp. (LQDA) has a current PS of 10.25. The 5-year average PS is 23.03. The thresholds are as follows: Strongly Undervalued below -7.27, Undervalued between -7.27 and 7.88, Fairly Valued between 38.19 and 7.88, Overvalued between 38.19 and 53.34, and Strongly Overvalued above 53.34. The current Forward PS of 10.25 falls within the Historic Trend Line -Fairly Valued range.

-29.67

P/OCF

Liquidia Corp. (LQDA) has a current P/OCF of -29.67. The 5-year average P/OCF is -6.95. The thresholds are as follows: Strongly Undervalued below -19.83, Undervalued between -19.83 and -13.39, Fairly Valued between -0.51 and -13.39, Overvalued between -0.51 and 5.93, and Strongly Overvalued above 5.93. The current Forward P/OCF of -29.67 falls within the Strongly Undervalued range.

-55.33

P/FCF

Liquidia Corp. (LQDA) has a current P/FCF of -55.33. The 5-year average P/FCF is -10.32. The thresholds are as follows: Strongly Undervalued below -25.75, Undervalued between -25.75 and -18.04, Fairly Valued between -2.60 and -18.04, Overvalued between -2.60 and 5.11, and Strongly Overvalued above 5.11. The current Forward P/FCF of -55.33 falls within the Strongly Undervalued range.

Liquidia Corp (LQDA) has a current Price-to-Book (P/B) ratio of 156.47. Compared to its 3-year average P/B ratio of 15.81 , the current P/B ratio is approximately 889.76% higher. Relative to its 5-year average P/B ratio of 10.85, the current P/B ratio is about 1342.72% higher. Liquidia Corp (LQDA) has a Forward Free Cash Flow (FCF) yield of approximately -5.10%. Compared to its 3-year average FCF yield of -7.17%, the current FCF yield is approximately -28.89% lower. Relative to its 5-year average FCF yield of -15.03% , the current FCF yield is about -66.10% lower.

156.47

P/B

Median3y

15.81

Median5y

10.85

-5.10

FCF Yield

Median3y

-7.17

Median5y

-15.03

Competitors Valuation Multiple

The average P/S ratio for LQDA's competitors is 30.30, providing a benchmark for relative valuation. Liquidia Corp Corp (LQDA) exhibits a P/S ratio of 10.25, which is -66.16% above the industry average. Given its robust revenue growth of 141.51%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Centessa Pharmaceuticals PLC

Loss

2.24B

FOLD.O

Amicus Therapeutics Inc

Agios Pharmaceuticals Inc

Tarsus Pharmaceuticals Inc

IDEAYA Biosciences Inc

120.60

2.15B

Performance Decomposition

Market capitalization of LQDA increased by 191.06% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 3.66M to 8.84M.

The secondary factor is the P/E Change, contributed 89.50%to the performance.

Overall, the performance of LQDA in the past 1 year is driven by Revenue Growth. Which is more sustainable.

141.51%

3.66M → 8.84M

Revenue Growth

-39.95%

-783.49 → -470.51

Margin Expansion

89.50%

-8.04 → -15.24

P/E Change

191.06%